ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
A complete sojourn on nanotechnological advancements and nanocarrier applications in psoriasis management.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Can Microneedle-Nanocarrier Platforms Deliver True Tolerogenic Immunotherapy for Psoriasis?Vaccines · 2026Review
- Shikonin-Loaded ROS-Responsive Microneedles for Psoriasis Therapy: Formulation, Transdermal Delivery, and Mechanistic Evaluation.Pharmaceutics · 2026Article
- Intelligent Diagnosis and Treatment of Psoriasis Research: A Bibliometric Analysis from 2005-01-01 to 2025-12-31.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis, a chronic autoimmune and non-communicable skin disease, affects 2-3% of the global population, creating a significant financial burden on healthcare systems worldwide. Treatment approaches are categorized based on disease severity, with first-line therapy focusing on topical treatments and second-line therapy encompassing phototherapy, systemic therapy, and biological therapy. Transdermal drug delivery methods present a promising alternative by enhancing drug absorption through the skin, potentially improving therapeutic outcomes while minimizing systemic adverse effects. Among these, microneedles (MNs) emerge as an innovative transdermal delivery device offering controlled and sustained drug release, reduced systemic exposure, and painless, minimally invasive targeted drug delivery, making them highly suitable for managing skin-related immune disorders. Other transdermal techniques, such as sonophoresis, patches, iontophoresis, and electroporation, also play critical roles in psoriasis treatment. Nanotechnological approaches offer transformative solutions to overcome the limitations of traditional formulations by enhancing efficacy, reducing dosing frequency, and minimizing dose-dependent side effects. Various nanocarriers, including liposomes, ethosomes, transferosomes, niosomes, solid lipid nanoparticles (SLNs), liquid crystalline nanoparticles (LCNPs), nanoemulsions (NEs), and micelles, demonstrate significant potential to improve drug penetration, targeted distribution, safety, and efficacy. This review aims to comprehensively analyze the advancements in nanotechnological approaches and nanocarrier applications for psoriasis management. It discusses the types, pathophysiology, and history of psoriasis while exploring current treatment strategies, including herbal formulations and nanotechnology-based interventions. The review also evaluates the potential of nanotechnological advancements as innovative therapeutic options, emphasizing their mechanisms, benefits, and clinical applicability in addressing the shortcomings of conventional therapies. Together, these insights highlight nano-formulations as a promising frontier for effective psoriasis management.
Indexed as
Identifiers
39847054What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.